November 22, 2022
Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis
READ MORE
November 8, 2022
Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA® (tapinarof) cream, 1% in Atopic Dermatitis
READ MORE
October 13, 2022
Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference
READ MORE
September 7, 2022
Fortune and Great Place to Work® Name Dermavant One of the Best Small Workplaces™ and Best Workplaces in Biopharma™ in 2022
READ MORE
August 24, 2022
Dermavant to Present New Data from Phase 3 Trial Program of VTAMA® (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress
READ MORE
June 28, 2022
VTAMA® (tapinarof) cream, 1% PSOARING 3 Final Data Published in JAAD
READ MORE
